Skip to main content.

Studies Currently Enrolling

KU School of Medicine-Wichita Center for Clinical Research is looking for volunteers to participate in research studies.

Studies may include:

  • time/travel reimbursement
  • medication
  • clinical evaluations
  • medical tests
  • physical exams


View details of current studies:

Pediatrics

  • Constipation (ages 6-17) - A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy study of linaclotide administered orally to children, Ages 6 to 17 years, with functional constipation (FC).
  • Depression (ages 7+) - A study for patients ages 7-17 years old with major depressive disorder. The purpose of this study is to examine the safety and efficacy of levomilnacipran (Fetzima) in children. Participants are randomized to one of three groups: placebo, levomilnacipran (Fetzima) or fluoxetine (Prozac). There is a $50 compensation per visit for time and travel. A parent or guardian is required to attend each of the nine visits.
  • Research database - You are being asked to participate in our research participant database. The purpose of this database is to collect personal health information to determine if you qualify for any current and/or future research studies.

Adults

  • ACTIV-6 COVID-19 treatment – A research study to see if certain FDA-approved medications can help people with mild to moderate COVID-19 feel better faster and stay out of the hospital. Participants must be at least 30 years old, have tested positive for COVID-19 within 10 days and have at least two of a specific set of symptoms. Participants will receive by mail either a placebo or a study medication, answer short, daily online surveys for 14-28 days and complete a follow-up survey after 90 days. A gift card of up to $100 will be awarded upon completion of the study.
  • COPD - A multi-center, randomized, 36-month, parallelgroup, non-inferiority, Phase 3 study to compare the effectiveness of 500 mcg QD oralternate regimen of roflumilast (Daliresp) therapy versus 250 mg QD, 500 mg QD three times per week, or alternate regimen of azithromycin therapy to prevent COPD exacerbations.
  • COVID-19 Vaccine - Phase 3 Efficacy Trial of a vaccine to prevent COVID-19 disease.
  • Depression - A 12-week study on adults with depression. Participants must be 18 to 80 years of age, have been diagnosed with major depressive disorder (MDD) for at least 12 weeks and have failed 2-5 trials of antidepressants or psychotherapy in the current major depressive episode. The study includes 8 office visits and pays $50 per visit.
  • Early Alzheimer's -  A 23-month study, with an optional extension phase study for an additional two years, for participants ages 50-90 years old with Alzheimer's or those with history of reported memory decline over the last year. This is a Phase 3 study that will test the effectiveness of a study drug, a monoclonal antibody, as a possible treatment. Compensation is provided for time and travel, and the study drug is provided free of charge.
  • Research database - You are being asked to participate in our research participant database. The purpose of this database is to collect personal health information to determine if you qualify for any current and/or future research studies.
  • Personality disorders - Genetic profile and ancestry information for participants 18 years and older, with personality disorders.
  • Schizophrenia - A Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, efficacy, and pharmacokinetics of miricorilant (CORT118335) in obese adult patients with schizophrenia and recent weight gain while taking antipsychotic medications.

Ready to participate or have questions?

Contact us at 316-293-1833 or complete the online interest form:

Complete the Clinical Trials Interest Form
KU School of Medicine-Wichita

1010 North Kansas
Wichita, KS 67214-3199
316-293-2635